Expert outlines how to manage common skin and GI side effects of daraxonrasib in pancreatic cancer

Dr Pant, MD, a professor at MD Anderson Cancer Center, discussed the safety profile of daraxonrasib, a RAS(ON) multi-selective inhibitor being studied in pancreatic ductal adenocarcinoma.

The drug has shown significant efficacy in previously treated metastatic PDAC in the phase 3 RASolute 302 trial and promising signals in first-line settings from early-phase studies.

The most frequent adverse event is a dermatologic rash, occurring in roughly 90% of patients, though most are manageable; severe grade 3-4 rashes are less common.

Pant emphasized proactive monitoring and supportive care to address both skin and gastrointestinal toxicities, noting that experience will improve as more patients are treated.

He concluded that better management of these side effects will help maximize the therapeutic benefit of daraxonrasib in ongoing and future trials.